|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2001-5-14
|
|
pubmed:abstractText |
We recently presented evidence for tumor site and gender-specificity in the survival benefit from adjuvant chemotherapy in Stage III colorectal cancer (CRC). In the current study, we examined whether p53 alteration or the microsatellite instability (MSI) phenotype provide additional predictive information in CRC patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1343-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11350904-Adult,
pubmed-meshheading:11350904-Aged,
pubmed-meshheading:11350904-Colorectal Neoplasms,
pubmed-meshheading:11350904-Female,
pubmed-meshheading:11350904-Genetic Markers,
pubmed-meshheading:11350904-Humans,
pubmed-meshheading:11350904-Male,
pubmed-meshheading:11350904-Microsatellite Repeats,
pubmed-meshheading:11350904-Middle Aged,
pubmed-meshheading:11350904-Multivariate Analysis,
pubmed-meshheading:11350904-Mutation,
pubmed-meshheading:11350904-Neoplasm Staging,
pubmed-meshheading:11350904-Predictive Value of Tests,
pubmed-meshheading:11350904-Prognosis,
pubmed-meshheading:11350904-Survival Analysis,
pubmed-meshheading:11350904-Tumor Suppressor Protein p53
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.
|
|
pubmed:affiliation |
Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, Australia.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
